SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

USRM RSS Feed
Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: TheHungryHippo, Papa Bear, BluSkies, StaleyCornell, buythebuy, mtlebomac
Search This Board: 
Last Post: 4/26/2017 1:48:23 AM - Followers: 828 - Board type: Free - Posts Today: 15



http://us-stemcell.com/en/home-2/





 

A COMMITMENT TO EXCELLENCE

Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 

 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.

 

.

Management:

Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
 
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.
 

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.
 

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame
 

 

Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director
     

 



Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
     
     

     
    
USRM - Daily Candlesticks






 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
USRM News: Significant Updates on the Following Companies and New Coverage 04/20/2017 09:00:00 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:49:04 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:47:59 AM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/31/2017 04:02:24 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/17/2017 04:02:15 PM
PostSubject
#52397  Sticky Note This is the guy who is investing up Vita Nova Stocks 04/15/17 09:22:22 AM
#42457  Sticky Note THIS IS A MUST READ slam4202 03/30/17 07:05:37 AM
#42449  Sticky Note CEO BLOG / FDA "On regulatory news, BluSkies 03/30/17 04:51:30 AM
#26891  Sticky Note $USRM ALL IN ONE DD Post for Investors: TheHungryHippo 03/09/17 05:25:50 AM
#26168  Sticky Note Thoughts? http://3030health.libsyn.com/episode-06-an-interview-with-kristin-com BluSkies 03/07/17 09:49:57 PM
#55009   Damn I'm excited! babydaddy 04/26/17 01:48:23 AM
#55008   slapping the ask for 99000 shares in the babydaddy 04/26/17 01:47:30 AM
#55007   remember when USRM was #1 on the leader MFE23 04/26/17 01:45:05 AM
#55006   gn folks Work Harder 04/26/17 01:33:26 AM
#55005   fwiw, he is usrm's attorney Work Harder 04/26/17 01:31:39 AM
#55004   Congrats with your wedding in september. i hope winnaar123 04/26/17 01:30:02 AM
#55003   https://www.nih.gov/ I'm different Work Harder 04/26/17 01:23:07 AM
#55002   In 1981, Mr. Mitrani graduated from Harvard Law School Work Harder 04/26/17 01:21:04 AM
#55001   NHLBI? Carl Spackler 04/26/17 01:20:21 AM
#55000   Attention all investors please set your shares at pennyking130 04/26/17 01:20:10 AM
#54999   its a much bigger deal now that he bubleman 04/26/17 01:15:25 AM
#54998   So, know who oversees the fda trials? Work Harder 04/26/17 01:08:16 AM
#54997   Yeah that's what I thought Leggy 04/26/17 12:47:51 AM
#54996   The stock is down about 50% since his Carl Spackler 04/26/17 12:42:44 AM
#54995   Awesome! I Sure hope you are right. I coachvw 04/26/17 12:11:07 AM
#54994   This roller coaster ride has made me grumpy Gary18 04/25/17 11:54:01 PM
#54993   @Devil Tower sorry bud dont have private damain22 04/25/17 11:47:01 PM
#54992   I hope so. I've got 288,000 at an Leggy 04/25/17 11:36:19 PM
#54991   The beginning of a new era in regenerative medicine. emit 04/25/17 10:51:16 PM
#54990   This will have an immediate impact tomorrow IMO. cager 04/25/17 10:49:18 PM
#54989   YOU WILL GET TO 50 , NO WORRY, power11 04/25/17 10:48:27 PM
#54988   RMAT approval will be under his "watch" bubleman 04/25/17 10:36:49 PM
#54987   I know his stance on stem cells, but Leggy 04/25/17 10:21:14 PM
#54986   Stay single, invest your money instead! Rubyt 04/25/17 10:11:35 PM
#54985   Tomorrow will be huge with Scott Gottileb being tamtam84 04/25/17 09:53:37 PM
#54984   Wedding in September! Plenty of time USRM will tamtam84 04/25/17 09:51:49 PM
#54983   From the dd board Work Harder 04/25/17 09:45:50 PM
#54982   When do you plan on getting married? (LOL) coachvw 04/25/17 09:37:46 PM
#54981   Im putting a 60 day sell order on pennystocKING13 04/25/17 09:33:50 PM
#54980   I CAN SELL 1/2 MY SHARES WHEN GETS tamtam84 04/25/17 09:24:47 PM
#54979   TOMORROW WILL BE HUGE https://www.usatoday.com/story/opinion/2017/04 tamtam84 04/25/17 09:21:59 PM
#54978   Let's get to .50 first! Rubyt 04/25/17 09:21:03 PM
#54977   Wednesdays are always lucky 0mn1 04/25/17 09:19:35 PM
#54976   USRM STATUS REPORT ::: NOTHING HAS CHANGED.... power11 04/25/17 09:18:00 PM
#54975   Boomtime soon !!! Joeymc77 04/25/17 09:10:38 PM
#54974   No..can come at anytime. Staypositive1 04/25/17 08:23:39 PM
#54973   Does the news have to come pre or th340385 04/25/17 08:21:54 PM
#54972   $USRM The daily chart on this page (to trading.jeff 04/25/17 08:19:41 PM
#54971   Gah, I'm just waiting to sell a few umyeahright 04/25/17 07:48:11 PM
#54970   Scott Gottlieb supports "right to try" movement in pennystocKING13 04/25/17 07:47:15 PM
#54969   By the way boss, that percentage figure is damain22 04/25/17 07:01:29 PM
#54968   Prolly people straddling the market waiting in the damain22 04/25/17 06:54:47 PM
#54967   Remember Scott Gottieb is being sworn in tomorrow. Jake731 04/25/17 06:47:13 PM
#54966   This will be going to $1 after RMAT. GoldenMind 04/25/17 06:44:25 PM
#54965   Less 3mil vol and 54% short Devils Tower 04/25/17 06:40:44 PM
#54964   Holding long and strong $$$$ pennyking130 04/25/17 06:35:05 PM
#54963   Agreed, i think the market did the math damain22 04/25/17 06:20:41 PM
#54962   break and hold above the upper bolli on afterhoursearnings 04/25/17 05:50:01 PM
#54961   I don't think so. I think any BearDickPunch 04/25/17 05:09:17 PM
#54960   Doesn't mean will hold tomorrow marina22 04/25/17 04:58:56 PM
PostSubject